Our data demonstrated that several genes in key cancer pathways (EGFR-PI3K-Akt-mTOR, NOTCH, NF-κB, DNA repair) were mutated, suggesting their potential use as predictive markers for targeted therapies to improve survival and outcome of NPC patients. This evidence concerns the gene EGFR and cancer.